Recently, the Class 1 innovative drug Garsorasib Tablets (trade name: 安方宁) of Shanghai Chia-tai Tianqing Pharmaceutical Technology Development Co. Ltd. is approved with conditions for marketing through the priority review and approval procedure by NMPA in China. This drug is indicated for adult patients with advanced non-small cell lung cancer (NSCLC) carrying the Kirsten rat sarcoma viral oncogene (KRAS) G12C mutation who have received at least one systemic treatment, providing a new treatment option for patients.